NCT06886074View on ClinicalTrials.gov

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2027

Conditions
Acute Lymphoblastic LeukemiaMeasurable Residual Disease (MRD)
Interventions
DRUG

Short course of blinatumomab

"Patients will receive 175 mcg of blinatumomab trough out seven days in a 24-hours infusion.~Blinatumomab therapy will be assigned 17.5 mcg per day for the first 2 days. Then blinatumomab 28 mcg per day for 5 days (completing 7 days). A single intravenous 20 mg dose of dexamethasone will be applied one hour before starting dose."

Trial Locations (1)

64460

RECRUITING

Hospital Universitario Dr. Jose E. Gonzalez, Monterrey

All Listed Sponsors
lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER